vir-5500
Generic: Anti-PSMA/CD3 Protease-activated T-cell Engager AMX-500
vir-5500: sourced relationships with 1 company · 1 clinical trial tracked.
vir-5500 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect vir-5500 to VIR; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could vir-5500 → VIR affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
metastatic castration-resistant prostate cancer (mCRPC)
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Vir Biotechnology, Inc. (VIR) metastatic castration-resistant prostate cancer (mCRPC) | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer
Primary endpoint: All parts: Incidence of treatment emergent anti-drug antibodies (ADAs) to VIR-5500
Interventionalopen437 targetStarted 2023-08Completion 2027-0922 sites · Australia, Spain, United Kingdom, United StatesAstellas Pharma Global Development, Inc.
Frequently asked questions
Which companies have sourced relationships with vir-5500?
vir-5500 has dated SEC/FDA relationship records for Vir Biotechnology, Inc..
How many clinical trials involve vir-5500?
BioSniper tracks 1 clinical trial involving vir-5500.